ScholarLens Back to search
2019•Southern African Journal of Critical CareOpen access

Quinine – a time for re-evaluation?

Guy Antony Richards

Open full text 0 citations

Abstract

Quinine was the drug of choice for severe malaria until 2005 and was used extensively in South Africa for this purpose. As discussed in this issue of the SAJCC by Mathiba et al . from Chris Hani Baragwanath Hospital (CHBH), two large randomised controlled trials (SEAQUAMAT (South East Asian Quinine Artesunate Malaria Trial) and AQUAMAT (African Quinine v. Artesunate Malaria Trial)) conducted in adults and children, respectively found that mortality was significantly lower with intravenous artesunate and as such it became the recommended agent for severe malaria.

Open-access reader

About this research paper

What this paper is about

Quinine was the drug of choice for severe malaria until 2005 and was used extensively in South Africa for this purpose. As discussed in this issue of the SAJCC by Mathiba et al . from Chris Hani Baragwanath Hospital (CHBH), two large randomised controlled trials (SEAQUAMAT (South East Asian Quinine Artesunate Malaria Trial) and AQUAMAT (African Quinine v. Artesunate Malaria Trial)) conducted in adults and children, respectively found that mortality was significantly lower with intravenous artesunate and as such it became the recommended agent for severe malaria.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Quinine was the drug of choice for severe malaria until 2005 and was used extensively in South Africa for this purpose. As discussed in this issue of the SAJCC by Mathiba et al . from Chris Hani Baragwanath Hospital (CHBH), two large randomised controlled trials (SEAQUAMAT (South East Asian Quinine Artesunate Malaria Trial) and AQUAMAT (African Quinine v. Artesunate Malaria Trial)) conducted in adults and children, respectively found that mortality was significantly lower with intravenous artesunate and as such it became the recommended agent for severe malaria.

Key concepts: Artesunate, Quinine, Malaria, Medicine, Severe Malaria, Plasmodium falciparum, Immunology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Quinine – a time for re-evaluation? — Research Paper | ScholarLens